We are very pleased with the progress we have made in delivering on our Forward, Faster strategy. We are on track with key regulatory milestones, and our innovation strategy, powered by our unique technology platforms and value-enriching collaborations, has significantly expanded our pipeline. With over 15 ongoing preclinical programs in oncology and immunology, our ambition to initiate at least one first-in-human study in 2025 and introduce at least two new clinical candidates annually starting in 2026, positions us strongly for sustained value creation.

Dr. Paul Stoffels, CEO and Chairman

Strengthened by our newest collaboration with Blood Centers of America, we are gearing up for our pivotal CAR-T studies and commercial readiness. We continue to evaluate business development opportunities and were happy to announce a clinical collaboration with an option to exclusively license Adaptimmune’s next-generation TCR T-cell therapy, uza-cel. We reaffirm our 2024 outlook, with key pipeline catalysts on track and cash burn guidance, excluding business development, in the range of €280-320 million.

Thad Huston, CFO and COO